Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023
02/16/2023 - 07:30 AM
Corporate presentation at 10:50 a.m. ET
NEW HAVEN, Conn. Feb. 16, 2023 Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced senior leadership will be presenting at the virtual Emerging Growth Conference on Wednesday, February 22 , at 10:50 a.m. ET .
This live online event will give existing shareholders and the investment community the opportunity to interact with Jennifer Good , President and CEO, David Clark , CMO, and Farrell Simon, SVP, Commercial and Strategy in real-time. The Trevi team will give a corporate presentation followed by a Q&A session.
In order to attend the conference, submit questions in advance, and receive updates, please register here: https://goto.webcasts.com/starthere.jsp?ei=1595541&tp_key=7d6588b9a9&sti=trvi
A live webcast of the corporate presentation will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com . An archived replay of the webcast will also be available on the Company's website, EmergingGrowth.com, and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference following the event.
About the Emerging Growth Conference The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
All sessions will be conducted through video webcasts and will take place in the Eastern time zone.
About Trevi Therapeutics, Inc.
For more information, visit www.TreviTherapeutics.com and follow the Company on Twitter and LinkedIn .
Investor Contact Katie McManus k.mcmanus@trevitherapeutics.com
Media Contact Rosalia Scampoli rscampoli@marketcompr.com
https://www.prnewswire.com/news-releases/trevi-therapeutics-to-present-at-the-emerging-growth-conference-on-february-22-2023-301748556.html
SOURCE Trevi Therapeutics, Inc.
TRVI Rankings
#2882 Ranked by Stock Gains
TRVI Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Pharmaceuticals: Major, Health Technology, Manufacturing, Medicinal and Botanical Manufacturing
About TRVI
trevi therapeutics, inc. is a late-stage biopharmaceutical company focused on developing nalbuphine® er for chronic pruritic conditions. pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. the company is pursuing several pruritic conditions for clinical development, including its lead indication of prurigo nodularis. prurigo nodularis is a chronic pruritic dermatologic condition characterized by the presence of pruriginous lesions (excoriative/ulcerative papules and nodules) on the skin. there are no approved therapies in the us or eu for this condition. nalbuphine® er is an oral extended release synthetic opioid with a dual mechanism of action, mu receptor antagonist and kappa receptor agonist, both of which have been shown in research to be effective in abolishing itch. because of nalbuphine® er’s unique dual mechanism of action, which has shown efficacy in addressing pruritus in human clinical trials, the company believes nalbuphine® er can
